Clinical Trial

A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy

Recruiting
View on ClinicalTrials.gov →
Summary
This is a post-marketing surveillance study conducted as part of the Risk Management Plan (RMP) for South Korea, to evaluate the safety and effectiveness of iptacopan in real-world clinical settings for the treatment of either PNH or C3G in Korean patients. Prospective data will be collected from patient medical records to address the objectives for all eligible populations.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-06-27
notable Trial sites expanded: 0 -> 3 locations 2026-06-27
Trial Details
NCT Number NCT07416162
Lead Sponsor Novartis Pharmaceuticals
Conditions Paroxysmal Nocturnal Hemoglobinuria, C3 Glomerulopathy
Enrollment 21 participants
Start Date 2026-06-15
Primary Completion 2029-02-01 (estimated)
Study Completion 2029-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-26